Cart
sales@molnova.com
DAPTA
CAS No. 106362-34-9
DAPTA( D-Ala-peptide T-amide; Adaptavir )
Catalog No. M29883 CAS No. 106362-34-9
DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 80 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 267 | In Stock |
|
| 50MG | 399 | In Stock |
|
| 100MG | 575 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
Biological Information
-
Product NameDAPTA
-
NoteResearch use only, not for human use.
-
Brief DescriptionDAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.
-
DescriptionDAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.(In Vitro):DAPTA (1 nM) inhibits HIV-1 replication in monocytes/macrophages (M/M) by >90%. DAPTA blocks HIV entry and prevents HIV-1 infection. DAPTA reduces CCR5 mAb binding in human primary macrophages. DAPTA potently blocks R5 gp120-mediated neuronal apoptosis. DAPTA is even more potent in preventing neuronal apoptosis than the CCR5 antagonist TAK-779. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5. DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5. DAPTA inhibits the binding of gp120BaL/sCD4 to CCR5 (Cf2Th/synR5) cells with IC50 of 55 ± 0.08 pM.
-
In VitroDAPTA (1 nM) inhibits HIV-1 replication in monocytes/macrophages (M/M) by >90%. DAPTA blocks HIV entry and prevents HIV-1 infection. DAPTA reduces CCR5 mAb binding in human primary macrophages. DAPTA potently blocks R5 gp120-mediated neuronal apoptosis. DAPTA is even more potent in preventing neuronal apoptosis than the CCR5 antagonist TAK-779. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5. DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5. DAPTA inhibits the binding of gp120BaL/sCD4 to CCR5 (Cf2Th/synR5) cells with IC50 of 55 ± 0.08 pM.
-
In Vivo——
-
SynonymsD-Ala-peptide T-amide; Adaptavir
-
PathwayMicrobiology/Virology
-
TargetHIV
-
Recptorgp120BaL/sCD4-CCR5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number106362-34-9
-
Formula Weight856.88
-
Molecular FormulaC35H56N10O15
-
Purity>98% (HPLC)
-
SolubilityH2O : 50 mg/mL (58.35 mM; Need ultrasonic)
-
SMILES——
-
Chemical NameSequence:Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH2
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Pollicita M, et al. Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells. Antivir Chem Chemother. 2007;18(5):285-95.
molnova catalog
related products
-
Doravirine
Doravirine (MK-1439, MK1439) is a novel, highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI) with IC50 of 12, 9.7, and 9.7 nM against WT, K103N, and Y181C reverse transcriptase (RT) mutants, respectively.
-
SAMT-247
SAMT-247 potent HIV-1 nucleocapsid protein NCp7 inhibitor with EC50 of 0.6 uM with low cellular toxicity (TC50>100 uM) in cultured and primary cells.
-
Zidovudine
A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS.
